Andere talen Dimerix Limited

Aandelen

DXB

AU000000DXB7

Beurs gesloten - Australian S.E. Andere beurzen 08:10:11 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,36 ^AUD	+7,46%		+12,50%	+75,61%

01/05	Dimerix verkrijgt goedkeuring voor plan voor pediatrisch onderzoek in het VK voor medicijn tegen nierziekte	MT
19/04	DIMERIX LIMITED : Euroz Hartleys ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	01/05
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	22/04
Dimerix Raises AU$20 Million for Kidney Disease Study	12/03
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	11/03
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Dimerix Limited Announces Appointment of Mark Diamond as Director	01/12
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	28/11
Dimerix Appoints Nonexecutive Chair	20/11
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	07/11
Dimerix Appoints Medical Chief	23-10-23
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	22-10-23
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	05-10-23
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	05-10-23
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	05-10-23
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	25-09-23
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	22-09-23
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	13-09-23
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30-08-23
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	05-07-23
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	03-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Dimerix Limited

Aandelen

DXB

AU000000DXB7

Andere talen

Filters